ACTR-70. IMPACT OF BEVACIZUMAB IN PATIENTS WITH RECURRENT GLIOBLASTOMA AND POOR PERFORMANCE STATUS

Clinical trials have showed that bevacizumab is beneficial for patients with recurrent glioblastoma and partially effective against newly diagnosed glioblastoma. However, glioblastoma patients with poor performance status (PS) were excluded from these clinical trials, and the efficacy of bevacizumab...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Argitaratua izan da:Neuro Oncol
Egile Nagusiak: Furuse, Motomasa, Kawabata, Shinji, Ikeda, Naokado, Nonoguchi, Naosuke, Tamura, Yoji, Kajimoto, Yoshinaga, Miyatake, Shin-Ichi, Kuroiwa, Toshihiko
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: Oxford University Press 2017
Gaiak:
Abstracts
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC5693094/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/neuonc/nox168.057
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak